Profound Medical (PRN) Price & Analysis

Compare

90 Followers

PRN Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$5.58 - C$12.74

Previous CloseN/A

Volume2.80K

Average Volume (3M)10.51K

Market Cap

C$186.03M

Enterprise ValueC$201.97M

Total Cash (Recent Filing)C$35.20M

Total Debt (Recent Filing)C$4.81M

Price to Earnings (P/E)―

Beta0.85

Next Earnings

Oct 30, 2025

EPS Estimate

-0.54

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding30,053,143

10 Day Avg. Volume7,768

30 Day Avg. Volume10,510

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$15.18

Price Target Upside150.08% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Financial PerformanceProfound reported Q4 results mostly in line with expectations and guided to 70%-75% growth this year, with the opportunity to reach triple-digit growth rates next year and beyond.

Insurance ReimbursementTULSA received a substantially higher reimbursement rate for 2025 from CMS than RARP, potentially making it more profitable for many institutions.

Regulatory ComplianceProfound is almost certainly unlikely to face any challenges on tariff concerns as the company is USMCA compliant, allowing their products to be traded duty-free.

Bears Say

Market CompetitionProfound is bringing more attention to the BPH opportunity and addressed Procept BioRobotics’ Aquablation, highlighting TULSA's unique versatility.

Profound Medical News

Profound Medical reports Q2 EPS (52c), consensus (40c)

Reports Q2 revenue $2.21M, consensus $4.73M. “The second quarter was characterized by some unfortunate timing, as we experienced...

22d ago

PROF

Profound Medical’s Earnings Call: A Balanced Outlook

Profound Medical (($TSE:PRN)) has held its Q2 earnings call. Read on for the main highlights of the call....

5d ago

PROF

Profound Medical to Participate in Lake Street’s BIG9 Conference

Profound Medical ( ($TSE:PRN) ) has shared an update. Profound Medical announced its participation in the Lake Street...

9d ago

PROF

Profound Medical Reports Q2 2025 Growth and New Innovations in Prostate Treatment

Profound Medical ( ($TSE:PRN) ) just unveiled an update. Profound Medical reported its second quarter 2025 financial results,...

22d ago

PROF

Profound Medical (PRN) Q2 Earnings Cheat Sheet

Profound Medical (PRN) is scheduled to report 2nd quarter earnings on 08/14/2025, after the market closes. Regarding Q2...

25d ago

PROF

Profound Medical to Announce Q2 2025 Financial Results

Profound Medical ( ($TSE:PRN) ) has issued an update. Profound Medical Corp. announced it will release its second...

1M ago

PROF

Profound Medical announces first commercial BPH treatment using TULSA-AI

Profound Medical (PROF) announces that the first commercial benign prostatic hyperplasia, BPH, treatment utilizing the TULSA-PRO system’s new...

3M ago

PROF

Profound Medical Partners with NFL Legend Leonard Wheeler to Promote TULSA-PRO

An update from Profound Medical ( ($TSE:PRN) ) is now available. Profound Medical Corp. has announced a partnership...

3M ago

PROF

Profound Medical enters agreement with former NFL player Leonard Wheeler

Profound Medical (PROF) has entered into a consulting agreement with Leonard Wheeler, a former NFL player turned entrepreneur,...

3M ago

PROF

Profound Medical Corp. Announces Successful Shareholder Meeting Outcomes

Profound Medical ( ($TSE:PRN) ) has provided an update. Profound Medical Corp. announced the successful voting results from...

4M ago

PROF

Profound Medical’s Earnings Call Highlights Growth and Innovation

Profound Medical (($TSE:PRN)) has held its Q1 earnings call. Read on for the main highlights of the call....

4M ago

PROF

Profound Medical downgraded to Outperform from Strong Buy at Raymond James

Raymond James analyst Michael Freeman downgraded Profound Medical (PROF) to Outperform from Strong Buy with a price target...

4M ago

PROF

Profound Medical Reports Strong Q1 2025 Growth and Highlights TULSA-PRO Advancements

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical Corp. reported an impressive 82% revenue growth...

4M ago

PROF

PRN Earnings this Week: How Will it Perform?

Profound Medical (PRN) is scheduled to report 1st quarter earnings on 05/08/2025, after the market closes. Regarding Q1...

4M ago

PROF

PRN FAQ

What was Profound Medical’s price range in the past 12 months?

Profound Medical lowest stock price was C$5.58 and its highest was C$12.74 in the past 12 months.

What is Profound Medical’s market cap?

Profound Medical’s market cap is C$186.03M.

When is Profound Medical’s upcoming earnings report date?

Profound Medical’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.

How were Profound Medical’s earnings last quarter?

Profound Medical released its earnings results on Aug 14, 2025. The company reported -C$0.718 earnings per share for the quarter, missing the consensus estimate of -C$0.511 by -C$0.207.

Is Profound Medical overvalued?

According to Wall Street analysts Profound Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Profound Medical pay dividends?

Profound Medical does not currently pay dividends.

What is Profound Medical’s EPS estimate?

Profound Medical’s EPS estimate is -0.54.

How many shares outstanding does Profound Medical have?

Profound Medical has 30,053,143 shares outstanding.

What happened to Profound Medical’s price movement after its last earnings report?

Profound Medical reported an EPS of -C$0.718 in its last earnings report, missing expectations of -C$0.511. Following the earnings report the stock price went down -20.955%.

Which hedge fund is a major shareholder of Profound Medical?

Currently, no hedge funds are holding shares in TSE:PRN

Profound Medical Stock Smart Score

Underperform

Fundamentals

Return on Equity

-106.37%

Trailing 12-Months

Asset Growth

-0.33%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Profound Medical (PRN) Earnings & Revenues

Historic Earnings Reports

PRN Stock 12 Month Forecast

Average Price Target

C$15.18

▲(150.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"C$5","16":"C$16","7.75":"C$7.75","10.5":"C$10.5","13.25":"C$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.18053801,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$15.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$15.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.18053801,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$15.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,7.75,10.5,13.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.78,8.349272154615385,8.91854430923077,9.487816463846153,10.057088618461538,10.626360773076922,11.195632927692307,11.764905082307692,12.334177236923075,12.90344939153846,13.472721546153846,14.041993700769229,14.611265855384614,{"y":15.18053801,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.78,8.34923076923077,8.918461538461539,9.487692307692308,10.056923076923077,10.626153846153846,11.195384615384615,11.764615384615386,12.333846153846153,12.903076923076924,13.472307692307691,14.041538461538462,14.61076923076923,{"y":15.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.78,8.349272154615385,8.91854430923077,9.487816463846153,10.057088618461538,10.626360773076922,11.195632927692307,11.764905082307692,12.334177236923075,12.90344939153846,13.472721546153846,14.041993700769229,14.611265855384614,{"y":15.18053801,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.36,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >